HOME > Investors > Press Releases
Subject AARP Calls ViroMed’s VM202 “Hope” for Peripheral Neuropathy
Writer ViroMed
Date 2018/04/12

AARP Calls ViroMed’s VM202 “Hope” for Peripheral Neuropathy

 

HGF isoform-based novel drug by ViroMed obtained indication patent from USPTO for Diabetic Peripheral Neuropathy Increasingly more patients seek to participate in VM202 phase III clinical trial in US 

 

 April 2018, SEOUL, Korea - In March, the AARP (American Association of Retired Persons) mentioned that VM202, developed by a Korean biotech ViroMed, is giving hope to patients with diabetic peripheral neuropathy (DPN) as it may greatly help improving their condition. 

 

 ViroMed is currently moving ahead with its VM202 gene therapy program, using the HGF isoform-based novel drug to target DPN. The company recently secured the US patent for VM202. 

 

 Dr. Miwon Son, R&D Director of ViroMed, commented, “The target indications of VM202 are likely to be expanded to various cardiovascular or neurologic diseases. Two phase III clinical trials are underway in the US, targeting DPN and non-healing diabetic foot ulcer.” 

 

 DPN is one of the common complications of diabetes that manifests symptoms of neuropathic pain. Patients experience not only tingling pain at the end of their feet but, in severe cases, abnormally extreme pain resembling electrostimulation as well. About 30-50% of diabetics are known to suffer from DPN. Pain medication is prescribed for these patients, but a therapeutic agent that is capable of reversing diabetic neuropathy has not yet been developed.

 

 In the meantime, ViroMed recently acquired US patent for VM202-DPN, a new drug candidate for the treatment of diabetic neuropathy based on plasmid DNA that may induce the regeneration of nerve cells and microvasculature (patent title: Gene therapy for diabetic neuropathy using an HGF isoform). Patients administered with VM202 in the phase II clinical trial showed more than 50% pain reduction and improvement in their ability to perceive a very light touch.  

 

 "This patent is for the first invention in the world that may treat or prevent diabetic neuropathy," said Dr. Son. "Securing a patent in the US, which accounts for 50% of the global market, means there is great commercial value."

 ViroMed has successfully completed phase I and phase II clinical trials in the US with phase III currently underway. Since the AARP introduced VM202 as a new drug for patients suffering from diabetic neuropathy, there has been a rapid increase in the number of patients applying to participate in the phase III clinical trial.

  

Translation by English Editor 

Original Korean text: http://www.aktv.co.kr/news/articleView.html?idxno=53146

News report video: https://www.youtube.com/watch?v=d-KjnAP3Jxo

AARP news: https://www.aarp.org/health/conditions-treatments/info-2018/treatments-lupus-hepatitis-c-pain.html